Immuno-Oncology Assay Market Size to Reach $6.17 Billion by 2026

Pune, Maharashtra, India, February 24 2021 (Wiredrelease) Allied Analytics –:The Immuno-Oncology Assay Market size generated $2.76 billion in 2018, and is estimated to reach $6.17 billion by 2026, registering a CAGR of 10.6% from 2019 to 2026. The report offers an extensive analysis of changing market dynamics, key winning strategies, business performance, major segments, and competitive scenarios.

Request for Sample Report at: https://www.alliedmarketresearch.com/request-sample/6444

Increase in research and development activities for cancer treatment and surge in usage of personalized medicines across the globe drive the growth of the global immuno-oncology assay market. However, high intial investment and shortage of skilled professionals are anticipated to restrain the growth of the market. Furthermore, government initiatives to encourage biotech research is likely to create new growth opportunities during the forecast period.

Covid-19 scenario:

The demand for immuno-oncology assay is expected to decline during the Covid-19 pandemic due to reduction in testing rates and postponement of cancer diagnosis.The repurposing of lab resources toward providing Covid-19 testing has impacted the ability of labs involved in oncology testing, due to which, the testing rate has been declined.According to Diacuetics, newly diagnosed colorectal cancer, breast cancer, and lung cancer patients has been dropped by 14.0%, 8.4% and 31.0% during Covid-19 pandemic. Owing to this reduction in patients, the demand for immuno-oncology assay is expected to roll down.

The report offers a detailed segmentation of the global immuno-oncology assay market based on product, technology, application, indication, and region.

Based on product, the consumables segment contributed to the largest share in 2018, accounting for nearly three-fourths of the total share, and is estimated to maintain its dominant position during the forecast period. However, the software segment is estimated to portray the highest CAGR of 11.8% during the forecast period.

Based on indication, the lung cancer segment accounted for the largest share in 2018, holding more than one-fifth of the total share, and is expected to maintain the largest share throughout the forecast period. However, the colorectal cancer segment is expected to register the highest CAGR of 12.3% from 2019 to 2026.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/6444

Based on region, North America contributed the highest share, accounting for more than two-fifths of the total market share in 2018, and will maintain its dominance throughout the forecast period. However, Asia-Pacific is expected to grow at the highest CAGR of 12.9% from 2019 to 2026.

Leading market players analyzed in the research include Thermo Fisher Scientific Inc., Luminex Corporation, Bio-Rad Laboratories Inc., Illumina Inc., QIAGEN N.V., Abcam PLC, Becton, Dickinson and Company, Meso Scale Diagnostics LLC, Seegene Inc., and Randox Laboratories Ltd.

This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.